[go: up one dir, main page]

GR1011003B - Nutritional supplement for treating bone density loss - osteopenia - Google Patents

Nutritional supplement for treating bone density loss - osteopenia

Info

Publication number
GR1011003B
GR1011003B GR20240100145A GR20240100145A GR1011003B GR 1011003 B GR1011003 B GR 1011003B GR 20240100145 A GR20240100145 A GR 20240100145A GR 20240100145 A GR20240100145 A GR 20240100145A GR 1011003 B GR1011003 B GR 1011003B
Authority
GR
Greece
Prior art keywords
nutritional supplement
pharmaceutically acceptable
acceptable derivative
bone density
treating bone
Prior art date
Application number
GR20240100145A
Other languages
Greek (el)
Inventor
Βασιλειος Παναγιωτοπουλος
Μαρινα Ρουσσακη
Σοφια-Αντιγονη Τσατσουλη
Αποστολια Ζαρμπαλα
Τιμοθεος-Αλεξανδρος Λουκας
Μιχαηλ Παπαδουρακης
Ελενη Χοντζοπουλου
Στεφανος Κωνσταντινου Χριστοδουλου
Κωνσταντινος Ιωαννη Τσιαντας
Original Assignee
Cloudpharm Private Company,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cloudpharm Private Company, filed Critical Cloudpharm Private Company,
Priority to GR20240100145A priority Critical patent/GR1011003B/en
Publication of GR1011003B publication Critical patent/GR1011003B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition or a nutritional supplement composition or a nutraceutical composition for treating bone density loss, in general. In particular, the present invention relates to a pharmaceutical composition or nutritional supplement comprising a therapeutically effective amount of quercetin or a pharmaceutically acceptable derivative thereof in combination with a therapeutically effective amount of naringin or a pharmaceutically acceptable derivative thereof in combination with a therapeutically effective amount of hesperidin or a pharmaceutically acceptable derivative thereof and at least one other substance such as calcium citrate and vitamin D3 (cholecalciferol) or a pharmaceutically acceptable derivative thereof in combination with fructo-oligosaccharides or galacto-oligosaccharides or inulin for use in the treatment of osteoporosis. Furthermore, the invention relates to the preparation process of said composition.
GR20240100145A 2024-02-28 2024-02-28 Nutritional supplement for treating bone density loss - osteopenia GR1011003B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20240100145A GR1011003B (en) 2024-02-28 2024-02-28 Nutritional supplement for treating bone density loss - osteopenia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20240100145A GR1011003B (en) 2024-02-28 2024-02-28 Nutritional supplement for treating bone density loss - osteopenia

Publications (1)

Publication Number Publication Date
GR1011003B true GR1011003B (en) 2025-07-22

Family

ID=96809583

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20240100145A GR1011003B (en) 2024-02-28 2024-02-28 Nutritional supplement for treating bone density loss - osteopenia

Country Status (1)

Country Link
GR (1) GR1011003B (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025350A1 (en) * 2000-06-12 2002-02-28 Idrees Siddiqui Composition and method for correcting a dietary phytochemical deficiency
JP2002234844A (en) * 2000-12-05 2002-08-23 Toyo Seito Kk Bone density enhancer and its use
US6812215B2 (en) * 2000-06-02 2004-11-02 MERCK Patent Gesellschaft mit beschränkter Haftung Compositions for the treatment of inflammatory joint diseases and osteoporosis
US20070190209A1 (en) * 2006-02-10 2007-08-16 Mannatech, Inc. All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
WO2011060123A1 (en) * 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
JP5371415B2 (en) * 2008-12-24 2013-12-18 王子コーンスターチ株式会社 Bone density reduction inhibiting composition
US8859612B2 (en) * 2002-06-28 2014-10-14 Institut National De La Recherche Agronomique (Inra) Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation
CN110934883A (en) * 2019-12-14 2020-03-31 湛江广医医药科技开发有限公司 A group of naringin preparations for improving osteoporosis in men and preventing fractures

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812215B2 (en) * 2000-06-02 2004-11-02 MERCK Patent Gesellschaft mit beschränkter Haftung Compositions for the treatment of inflammatory joint diseases and osteoporosis
US20020025350A1 (en) * 2000-06-12 2002-02-28 Idrees Siddiqui Composition and method for correcting a dietary phytochemical deficiency
JP2002234844A (en) * 2000-12-05 2002-08-23 Toyo Seito Kk Bone density enhancer and its use
US8859612B2 (en) * 2002-06-28 2014-10-14 Institut National De La Recherche Agronomique (Inra) Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation
US20070190209A1 (en) * 2006-02-10 2007-08-16 Mannatech, Inc. All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
JP5371415B2 (en) * 2008-12-24 2013-12-18 王子コーンスターチ株式会社 Bone density reduction inhibiting composition
WO2011060123A1 (en) * 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
CN110934883A (en) * 2019-12-14 2020-03-31 湛江广医医药科技开发有限公司 A group of naringin preparations for improving osteoporosis in men and preventing fractures

Similar Documents

Publication Publication Date Title
ES2369970T3 (en) NUTRITIONAL COMPOSITION FOR THE TREATMENT OF PRESSURE ULCERS.
BR9908030A (en) Pharmaceutical composition comprising one or more orally administered dose units, and processes for preparing it, for use thereof, and for treating a medical condition or disorder in an individual in whom treatment with a cyclooxygenase-2 inhibitor is indicated
JP2014533729A (en) Medicament for treating infection of hepatitis C virus containing quercetin
US20020197330A1 (en) Method of dietary supplementation
Bozikas et al. Treatment of acute mania with topiramate in hospitalized patients
GR1011003B (en) Nutritional supplement for treating bone density loss - osteopenia
Conley et al. Prolonged treatment of pernicious anemia with vitamin B12
RU2013133998A (en) METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF OSTEOARTHRITIS
Lin et al. Rhein lysinate suppresses the growth of tumor cells and increases the anti-tumor activity of Taxol in mice
CN107106601A (en) For treating or preventing the pharmaceutical composition that the vitamin and mineral for the patient for receiving gastric bypass operation lacks
KR100675998B1 (en) Compositions Comprising a Mixture of Bioflavonols
EP3130337A1 (en) Combination of a urinary basifying agent and a uric acid crystallisation inhibitor for the treatment or prevention of renal lithiasis
WO2012166003A1 (en) Method for filling bone cavity formations with calcium
CN111012900B (en) Composition with bone mineral density increasing function and preparation method and application thereof
US9855305B2 (en) Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and prebiotics effective in preventing adverse effects associated with the use of proton-pump inhibitors
US20040005366A1 (en) Healthy bone formulation
Alalwan Nutraceuticals and their role in promoting musculoskeletal healthy aging.
JP2002003382A (en) Nutrient auxiliary composition for promoting articular cartilage regeneration and inhibiting cartilage reduction
US2907697A (en) Therapeutic compositions
JP2004123671A (en) Nutrient agent and digestive tract agent
EP1124561A1 (en) Compositions comprising a mixture of bioflavonols
KR102752511B1 (en) MSQ composition for improving lipid metabolism related diseases
Ali Impacts of Nutritional Involvements for Metabolic Acidosis in Patients with Chronic Renal Illness: Article Review
GB2640044A (en) Co-amorphous solid forms of flavonoids
IT9022342A1 (en) FORMULATIONS OF LYOPHILIZED AMINO ACIDS CONTAINING GLUTAMINE, THEIR PREPARATION AND USE IN THE PARENTERAL FEEDING

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20250808